Intellia Therapeutics (NASDAQ:NTLA) Raised to Outperform at William Blair

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat Ratings reports.

Several other brokerages also recently issued reports on NTLA. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, January 22nd. Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. Wells Fargo & Company reduced their price objective on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Robert W. Baird set a $7.00 price objective on Intellia Therapeutics in a research report on Tuesday, January 27th. Finally, KeyCorp set a $25.00 target price on Intellia Therapeutics in a research note on Wednesday, January 28th. Ten analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics has an average rating of “Hold” and a consensus price target of $19.14.

Intellia Therapeutics Stock Down 11.9%

NTLA opened at $13.60 on Monday. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25. The business’s 50 day moving average is $12.09 and its two-hundred day moving average is $13.10. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -3.55 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The company’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.27) earnings per share. Equities analysts expect that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Activity

In related news, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Birgit C. Schultes sold 8,508 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at $907,488.93. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,051 shares of company stock valued at $488,600 in the last three months. 3.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after purchasing an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 17.8% during the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after buying an additional 1,965,181 shares during the period. State Street Corp increased its holdings in Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after buying an additional 1,447,967 shares in the last quarter. Contrarius Group Holdings Ltd increased its holdings in Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after buying an additional 4,337,428 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its position in shares of Intellia Therapeutics by 2.7% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock valued at $47,435,000 after acquiring an additional 71,000 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.